On the morning of June 1, the signing and opening ceremony of the construction project of Hubei Tianshu Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianshu Pharmaceutical"), a holding subsidiary of Nanjing Vcare PharmaTech Co., Ltd. (hereinafter referred to as "Nanjing Vcare"), was successfully held in Yicheng, Hubei Province. Liu Yongqiang, chairman of Nanjing Vcare, signed an on-site contract with representatives of Yicheng People's Government. The signing and opening ceremony is one of the "three centralized" activities of the second quarter major project in Yicheng, Hubei Province. Xiangyang Municipal Party Committee and Municipal Government of Hubei Province, Yicheng Municipal Party Committee and Municipal Government, Yangtze River Fund, Investment in China, Hanjiang Investment and other relevant leaders attended the signing ceremony.
The smooth signing and starting of Tianshu Pharmaceutical Construction Project is an important step for Nanjing Weikel to improve the industrial chain, optimize the layout of the sector and focus on future development. This will further improve the comprehensive competitiveness of Nanjing Vcare in the CRO/CDMO whole industrial chain service sector, and will also greatly improve capacity, so as to provide customers with more comprehensive and valuable services. Nanjing Vcare will focus on the goal of "building a first-class chemical drug industry chain R & D service platform", based on Nanjing, out of Jiangsu, towards the whole country, facing the world, in the field of foreign drug industry chain R & D services ploughed deeply and ploughed, stable and distant.
About Nanjing Vcare
Nanjing Vcare PharmaTech Co., Ltd. is a wholly owned subsidiary established by Jiangsu Vcare PharmaTech Co., Ltd. in 2021, independently operating the CRO/CDMO sector business. With a registered capital of 100 million yuan, nearly 300 employees and revenue of more than 200 million yuan in 2021, it is a high-tech pharmaceutical company integrating "chemistry + pharmacy + medicine" one-stop CRO/CDMO services. Mainly engaged in innovative and generic CMC, clinical and registration (CRO) services; innovative drug contract R & D and production (CDMO) services; characteristic APIs, advanced intermediates and impurities production and sales.
Nanjing Vcare has many laboratories such as synthesis, preparation and analysis, nearly 300 synthetic fume hoods, 45 Kg laboratory ventilation rooms, more than 200 sets of international first-class experimental equipment such as various types of analysis, preparation, synthesis, biology and pharmacology and toxicology, establishes a R & D team with rich practical experience and solid professional technology, draws lessons from internationally advanced management and operation modes, has CDMO production and supply service capacity from pharmaceutical intermediates to APIs, has the integrated industrial chain service capacity from pharmaceutical CMC to clinical CRO research and registration, helps customers quickly obtain production approval documents and clinical trial approval documents, and effectively puts pressure on national collection and medical insurance negotiation costs.
Nanjing Vcare provides CRO/CDMO services for Novartis, Merck, TEVA, Glenmark, Polpharma, Chia Tai Tianqing, Hengrui, Shiyao, Qilu, Hansoh, Simcere, Aosaikang, Haizheng, Yangtze River and other well-known biomedical companies at home and abroad. Customers have been assisted to obtain 20 drug registration approval documents, 10 clinical approval documents, more than 50 registration applications are under application, and more than 3,000 supporting customized intermediates and APIs have been supplied; they have passed the on-site inspection by CFDA for 4 times in 2020. The Company shall make every effort to ensure the cost controllability and supply chain stability in the R & D and production stages of customers, and help customers' advantages enter the volume-based purchasing and national medical insurance negotiation. At present, customers have won 6 bids for the centralized collection and collection of approved varieties.
About Hubei Tianshu Pharmaceutical
Hubei Tianshu Pharmaceutical Co., Ltd. was established in 2016 and is located in Xiangyang (Yicheng) Fine Chemical Industrial Park, Hubei Provincial Chemical Park, covering an area of 130 mu, has built 80 mu. It is specialized in the production and sales of pharmaceutical intermediates and APIs. The products have been exported to South Korea, Europe and the United States, and have a high reputation and good reputation in the industry. Hubei Tianshu Pharmaceutical Co., Ltd. has a total of 14 utility model patents and 2 invention patents, and is applying for 2 international patents. It is now a high-tech enterprise in Hubei Province.
As a subordinate manufacturing sits of Nanjing Vcare, Hubei Tianshu Pharmaceutical undertakes an important link in the layout of the whole industrial chain of "Chemistry + Pharmacy + Medicine", further improving the ability of Nanjing Vcare CRO/CDMO to serve the whole industrial chain and enhancing the comprehensive competitiveness of the company. The Phase I project capacity of Hubei Tianshu includes an API production workshop and an intermediate production workshop, with the construction area of 2,000 square meters, including a non-cytotoxic tumor line and a common line, with a total of 34 reactors and a capacity of about 55 m ³; the intermediate workshop has a construction area of 3,000 square meters, including 5 production lines (including a hydrogenation line), equipped with 100 reactors including high and low temperature and hydrogenation, with a capacity of about 300 m ³. Facilities were designed and constructed in strict accordance with FDA and cGMP requirements to meet high-end customer requirements.
Talent Concept
Recruitment
Follow Us
